Moderna (MRNA) Long-Term Investments (2017 - 2026)

Moderna (MRNA) has 10 years of Long-Term Investments data on file, last reported at $2.3 billion in Q1 2026.

• On a quarterly basis, Long-Term Investments fell 6.91% year-over-year to $2.3 billion in Q1 2026; TTM through Mar 2026 was $2.3 billion, a 6.91% decrease from a year earlier, with the FY2025 full-year figure at $2.3 billion, down 6.34% from the prior year.
• Long-Term Investments for Q1 2026 stood at $2.3 billion, down from $2.3 billion in the prior quarter.
• Over the last five years, Long-Term Investments for MRNA reached as high as $10.2 billion in Q2 2022 and fell as low as $36.0 million in Q1 2023.
• Historically, Long-Term Investments has averaged $4.4 billion across 5 years, with a median of $2.5 billion in 2024.
• Across the five-year window, Long-Term Investments sank 99.61% in 2023 and jumped 10005.56% in 2024, its largest moves.
• Year by year, Long-Term Investments stood at $8.3 billion in 2022, then plunged by 43.77% to $4.7 billion in 2023, then sank by 46.68% to $2.5 billion in 2024, then slipped by 6.34% to $2.3 billion in 2025, then declined by 3.64% to $2.3 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $2.3 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.1 billion in Q3 2025.